Hence, our Evi1-transgenic model presents a unique opportunity to explore the role of EVI1 during the early stages of MDS, MDS/MPN, or AML diseases characterized by EVI1 overexpression. The gene discussed is RUNX1; the disease is acute myeloid leukemia.